Multicenter,Randomized,Double-blind,Placebo,Parallel-controlled,Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of Major Depressive Disorder (MDD)
Latest Information Update: 29 Apr 2025
At a glance
- Drugs LV 232 (Primary) ; Escitalopram
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Vigonvita Life Sciences
Most Recent Events
- 24 Apr 2025 Planned number of patients changed from 500 to 400.
- 24 Apr 2025 Planned End Date changed from 20 Feb 2026 to 20 Dec 2026.
- 24 Apr 2025 Planned primary completion date changed from 1 Feb 2026 to 1 Sep 2026.